Document Detail

Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.
MedLine Citation:
PMID:  23208323     Owner:  NLM     Status:  Publisher    
BACKGROUND: A limited sampling strategy (LSS) for estimating the area under the curve (AUC) of the prolonged-release formulation of tacrolimus (tacrolimus(PR)) is not available in pediatric patients, although the method is of real benefit to children. The objective of this study was to develop and validate a reliable and clinically applicable LSS using Bayesian estimation for estimating tacrolimus(PR) AUC in pediatric kidney transplant patients METHODS: The original tacrolimus pharmacokinetic dataset consisted of 22 full profiles from 22 pediatric kidney transplant patients. The Bayesian estimation method was used to develop the LSS. External validation was performed in an independent validation group which consisted of 20 full pharmacokinetic profiles from 12 pediatric kidney transplant patients. RESULTS: Bayesian estimator using C(0h) C(2h) and C(3h) gave the best predictive performance with a mean prediction error of 2.2 % in the external validation dataset. There was no correlation between the prediction error and age. The Bland-Altman analysis showed that the mean difference between the reference and Bayesian-estimated AUC(0-24) was 3.5 (95 % confidence interval -3.5-10.5) ng h/mL CONCLUSIONS: A reliable and clinically applicable LSS for estimating AUC(0-24) of tacrolimus(PR) was determined and validated in children. The prediction was unbiased and precise. It can be used as a routine procedure to perform AUC-based tacrolimus(PR) dosage optimization in pediatric renal transplant patients.
Wei Zhao; Anne Maisin; Véronique Baudouin; May Fakhoury; Thomas Storme; Georges Deschênes; Evelyne Jacqz-Aigrain
Related Documents :
3892853 - Malakoplakia of urinary bladder following cadaveric renal transplantation.
22172853 - Liver graft failure and hyperbilirubinemia in liver transplantation recipients after cl...
7447393 - Megaloblastic, dyserythropoietic anemia following arsenic ingestion.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-4
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  -     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pediatric Pharmacology and Pharmacogenetics, Assistance Publique Hôpitaux de Paris (AP-HP), INSERM Clinical Investigation Center CIC9202-Hôpital Robert Debré, 48 Boulevard Sérurier, 75935, Paris Cedex 19, France,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.
Next Document:  The pros and cons of propensity scores.